196 related articles for article (PubMed ID: 27422809)
1. CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.
Barker HE; Patel R; McLaughlin M; Schick U; Zaidi S; Nutting CM; Newbold KL; Bhide S; Harrington KJ
Mol Cancer Ther; 2016 Sep; 15(9):2042-54. PubMed ID: 27422809
[TBL] [Abstract][Full Text] [Related]
2. An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
Patel R; Barker HE; Kyula J; McLaughlin M; Dillon MT; Schick U; Hafsi H; Thompson A; Khoo V; Harrington K; Zaidi S
Radiother Oncol; 2017 Mar; 122(3):470-475. PubMed ID: 28131548
[TBL] [Abstract][Full Text] [Related]
3. Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances
Zeng L; Beggs RR; Cooper TS; Weaver AN; Yang ES
Mol Cancer Ther; 2017 Apr; 16(4):591-600. PubMed ID: 28138028
[TBL] [Abstract][Full Text] [Related]
4. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
Zeng L; Nikolaev A; Xing C; Della Manna DL; Yang ES
Mol Cancer Ther; 2020 Jun; 19(6):1279-1288. PubMed ID: 32371584
[TBL] [Abstract][Full Text] [Related]
5. G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1.
Busch CJ; Kröger MS; Jensen J; Kriegs M; Gatzemeier F; Petersen C; Münscher A; Rothkamm K; Rieckmann T
Radiother Oncol; 2017 Feb; 122(2):260-266. PubMed ID: 27939202
[TBL] [Abstract][Full Text] [Related]
6. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
Khan Z; Khan AA; Prasad GB; Khan N; Tiwari RP; Bisen PS
Radiother Oncol; 2016 Feb; 118(2):359-68. PubMed ID: 26747757
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
9. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
Sano D; Matsumoto F; Valdecanas DR; Zhao M; Molkentine DP; Takahashi Y; Hanna EY; Papadimitrakopoulou V; Heymach J; Milas L; Myers JN
Clin Cancer Res; 2011 Apr; 17(7):1815-27. PubMed ID: 21350000
[TBL] [Abstract][Full Text] [Related]
10. Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress.
Lindemann A; Patel AA; Tang L; Tanaka N; Gleber-Netto FO; Bartels MD; Wang L; McGrail DJ; Lin SY; Frank SJ; Frederick MJ; Myers JN; Osman AA
Mol Cancer Ther; 2021 Jul; 20(7):1257-1269. PubMed ID: 33947685
[TBL] [Abstract][Full Text] [Related]
11. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.
Macha MA; Rachagani S; Qazi AK; Jahan R; Gupta S; Patel A; Seshacharyulu P; Lin C; Li S; Wang S; Verma V; Kishida S; Kishida M; Nakamura N; Kibe T; Lydiatt WM; Smith RB; Ganti AK; Jones DT; Batra SK; Jain M
Oncotarget; 2017 Mar; 8(13):20961-20973. PubMed ID: 28423495
[TBL] [Abstract][Full Text] [Related]
12. Targeted radiosensitization by the Chk1 inhibitor SAR-020106.
Borst GR; McLaughlin M; Kyula JN; Neijenhuis S; Khan A; Good J; Zaidi S; Powell NG; Meier P; Collins I; Garrett MD; Verheij M; Harrington KJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1110-8. PubMed ID: 22981708
[TBL] [Abstract][Full Text] [Related]
13. Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.
Leiker AJ; DeGraff W; Choudhuri R; Sowers AL; Thetford A; Cook JA; Van Waes C; Mitchell JB
Clin Cancer Res; 2015 Jun; 21(12):2792-801. PubMed ID: 25724523
[TBL] [Abstract][Full Text] [Related]
14. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma--derived CD44(+)ALDH1(+) cells.
Chen YW; Chen KH; Huang PI; Chen YC; Chiou GY; Lo WL; Tseng LM; Hsu HS; Chang KW; Chiou SH
Mol Cancer Ther; 2010 Nov; 9(11):2879-92. PubMed ID: 21062915
[TBL] [Abstract][Full Text] [Related]
15. Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.
Stegeman H; Kaanders JH; Verheijen MM; Peeters WJ; Wheeler DL; Iida M; Grénman R; van der Kogel AJ; Span PN; Bussink J
Mol Cancer; 2013 Nov; 12(1):133. PubMed ID: 24192080
[TBL] [Abstract][Full Text] [Related]
16. Effects of paclitaxel in combination with radiation on human head and neck cancer cells (ZMK-1), cervical squamous cell carcinoma (CaSki), and breast adenocarcinoma cells (MCF-7).
Pradier O; Rave-Fränk M; Schmidberger H; Bömecke M; Lehmann J; Meden H; Hess CF
J Cancer Res Clin Oncol; 1999; 125(1):20-7. PubMed ID: 10037273
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation.
Samadder P; Suchánková T; Hylse O; Khirsariya P; Nikulenkov F; Drápela S; Straková N; Vaňhara P; Vašíčková K; Kolářová H; Binó L; Bittová M; Ovesná P; Kollár P; Fedr R; Ešner M; Jaroš J; Hampl A; Krejčí L; Paruch K; Souček K
Mol Cancer Ther; 2017 Sep; 16(9):1831-1842. PubMed ID: 28619751
[TBL] [Abstract][Full Text] [Related]
18. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.
Walton MI; Eve PD; Hayes A; Valenti MR; De Haven Brandon AK; Box G; Hallsworth A; Smith EL; Boxall KJ; Lainchbury M; Matthews TP; Jamin Y; Robinson SP; Aherne GW; Reader JC; Chesler L; Raynaud FI; Eccles SA; Collins I; Garrett MD
Clin Cancer Res; 2012 Oct; 18(20):5650-61. PubMed ID: 22929806
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.
Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870
[TBL] [Abstract][Full Text] [Related]
20. Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress.
Zhang Y; Lai J; Du Z; Gao J; Yang S; Gorityala S; Xiong X; Deng O; Ma Z; Yan C; Susana G; Xu Y; Zhang J
Oncotarget; 2016 Jun; 7(23):34688-702. PubMed ID: 27167194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]